Plus Therapeutics (PSTV) CFO granted RSUs and stock options package

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

PLUS THERAPEUTICS, INC. reported that Chief Financial Officer Andrew John Hugh MacIntyre acquired equity awards consisting of restricted stock units and stock options. He received 349,542 Restricted Stock Units, each representing a contingent right to one share of common stock, and 349,541 stock options with a right to buy common stock.

The RSUs vest in substantially equal 1/12th increments over twelve quarters, beginning on April 1, 2026 with the remaining portions vesting quarterly thereafter. The options vest over four years in substantially equal 1/48th monthly increments on each monthly anniversary of grant and also vest upon a change of control in accordance with his employment agreement.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Sims Andrew John Hugh MacIntyre

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	349,542	$0.00	--
Grant/Award	Stock Option (Right to Buy)	349,541	$0.00	--

Holdings After Transaction: Restricted Stock Units — 732,774 shares (Direct); Stock Option (Right to Buy) — 349,541 shares (Direct)

Footnotes (1)

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over twelve quarters in substantially equal 1/12th increments, commencing with 1/12th vesting on April 1, 2026 and the remainder vesting quarterly thereafter. The options vest over four years in substantially equal 1/48th increments on each monthly anniversary of the issuance and vest on a change of control in accordance with the Optionee's employment agreement.

Form 4 Insider Transactions: What Each Field Means →

02/27/2026 - 04:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sims Andrew John Hugh MacIntyre

(Last)

(First)

(Middle)

C/O PLUS THERAPEUTICS INC.

6420 LEVIT GREEN BOULEVARD, SUITE 310

(Street)

HOUSTON

77021

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0⁽¹⁾	02/25/2026		A		349,542		⁽¹⁾	⁽¹⁾	Common Stock	349,542	$0	732,774	D
Stock Option (Right to Buy)	$0.28	02/25/2026		A		349,541		⁽²⁾	02/24/2036	Common Stock	349,541	$0	349,541	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over twelve quarters in substantially equal 1/12th increments, commencing with 1/12th vesting on April 1, 2026 and the remainder vesting quarterly thereafter.

2. The options vest over four years in substantially equal 1/48th increments on each monthly anniversary of the issuance and vest on a change of control in accordance with the Optionee's employment agreement.

	Andrew Sims, as attorney-in-fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did PLUS THERAPEUTICS (PSTV) report for its CFO?

PLUS THERAPEUTICS reported that its Chief Financial Officer Andrew John Hugh MacIntyre received equity awards. He was granted 349,542 Restricted Stock Units and 349,541 stock options, both structured to vest over multi-year schedules based on continued service and change-of-control provisions.

How many Restricted Stock Units were granted to the PSTV CFO?

The CFO received 349,542 Restricted Stock Units. Each RSU represents a contingent right to receive one share of PLUS THERAPEUTICS common stock, vesting in 1/12th increments over twelve quarters starting April 1, 2026, with quarterly vesting thereafter tied to ongoing service.

What is the vesting schedule for the PLUS THERAPEUTICS CFO RSU grant?

The Restricted Stock Units vest ratably over twelve quarters. They vest in substantially equal 1/12th increments, with the first 1/12th portion vesting on April 1, 2026 and the remaining RSUs vesting on subsequent quarterly dates, aligning with a three-year service period.

What stock option grant did the PLUS THERAPEUTICS CFO receive?

The CFO received 349,541 stock options labeled as a right to buy common stock. These options vest over four years in substantially equal 1/48th increments each month and are also structured to vest on a change of control under his employment agreement terms.

How do the PSTV CFO stock options vest over time?

The options vest over four years in monthly installments. Vesting occurs in substantially equal 1/48th increments on each monthly anniversary of the issuance date and may fully vest upon a change of control in accordance with the CFO’s employment agreement.

Does the PLUS THERAPEUTICS CFO Form 4 show any stock sales or purchases?

The Form 4 shows only grant or award acquisitions, not open-market buys or sales. It reports awards of 349,542 Restricted Stock Units and 349,541 stock options, both classified as grant or award acquisitions rather than transactional purchases or disposals in the market.